Clinical trials assessing the antitumor activity of atezolizumab in combination with HER2 mAbs and chemotherapy for patients receiving early line treatment for HER2+ breast cancer are ongoing (NCT03125928, NCT03726879). The gene discussed is ERBB2; the disease is breast carcinoma.